{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T23:10:37Z","timestamp":1695942637383},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00108-023-01569-z","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:01:35Z","timestamp":1691139695000},"page":"823-829","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiale ATTR-Amyloidose","Transthyretin amyloid cardiomyopathy"],"prefix":"10.1007","volume":"64","author":[{"given":"Frauke","family":"Czepluch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"1569_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams\u00a0D, Gonzales-Duarte\u00a0A, O\u2019Riordan\u00a0WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"1569_CR2","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","volume":"108","author":"F Aus dem Siepen","year":"2019","unstructured":"Aus dem Siepen\u00a0F, Hein\u00a0S, Prestel\u00a0S et\u00a0al (2019) Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy. Clin Res Cardiol 108:1324\u20131330","journal-title":"Clin Res Cardiol"},{"key":"1569_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson\u00a0MD, Waddington-Cruz\u00a0M, Berk\u00a0JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N\u00a0Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"1569_CR4","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o\u00a0A, Narotsky\u00a0DL, Hamid\u00a0N et\u00a0al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart\u00a0J 38:2879\u20132887","journal-title":"Eur Heart J"},{"key":"1569_CR5","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy\u00a0T, Costes\u00a0B, Hag\u00e8ge\u00a0AA et\u00a0al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart\u00a0J 37:1826\u20131834","journal-title":"Eur Heart J"},{"key":"1569_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta\u00a0NR, Rissing\u00a0SM, Smith\u00a0J et\u00a0al (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27:52\u201358","journal-title":"Amyloid"},{"key":"1569_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia\u00a0P, Rapezzi\u00a0C, Adler\u00a0Y et al (2021) Diagnosis and treatment of cardiac amyloidosis. A\u00a0position statement of the European society of cardiology working group on myocardial and pericardial diseases. Eur J Heart Fail 23:512\u2013526","journal-title":"Eur J Heart Fail"},{"key":"1569_CR8","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore\u00a0JD, Maurer\u00a0MS, Falk\u00a0RH et\u00a0al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"1569_CR9","doi-asserted-by":"publisher","first-page":"e005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap\u00a0LG, Dominici\u00a0F, Wang\u00a0Y et al (2019) Epidemiology of cardiac amyloidosis associated heart failure hospitalization among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 12:e5407","journal-title":"Circ Heart Fail"},{"key":"1569_CR10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1les-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1les-L\u00f3pez\u00a0E, Gallego-Delgado\u00a0M, Guzzo-Merello\u00a0G et al (2015) Wild-type transthyretin amyloidosis as a\u00a0cause of heart failure with preserved ejection fraction. Eur Heart\u00a0J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"1569_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","volume":"8","author":"K Lindmark","year":"2021","unstructured":"Lindmark\u00a0K, Pilebro\u00a0B, Sundstr\u00f6m\u00a0T et\u00a0al (2021) Prevalence of wild type transthyretin cardiac amyloidosis in a\u00a0heart failure clinic. ESC Heart Fail 8:745","journal-title":"ESC Heart Fail"},{"key":"1569_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","volume":"7","author":"S Longhi","year":"2014","unstructured":"Longhi\u00a0S, Guidalotti\u00a0PL, Quarta\u00a0CC et al (2014) Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 7:531\u2013532","journal-title":"JACC Cardiovasc Imaging"},{"key":"1569_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","volume":"300","author":"N Maurizi","year":"2020","unstructured":"Maurizi\u00a0N, Rella\u00a0V, Fumagalli\u00a0C et\u00a0al (2020) Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 300:191\u2013195","journal-title":"Int J Cardiol"},{"key":"1569_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer\u00a0MS, Hanna\u00a0M, Grogan\u00a0M et\u00a0al (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey). J\u00a0Am Coll Cardiol 68:161\u2013172","journal-title":"J Am Coll Cardiol"},{"key":"1569_CR15","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B et\u00a0al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"1569_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini\u00a0G, Bellotti\u00a0V (2003) Molecular mechanisms of amyloidosis. N\u00a0Engl J Med 349:583\u2013596","journal-title":"N Engl J Med"},{"key":"1569_CR17","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3390\/genes12070955","volume":"12","author":"AM Minnella","year":"2021","unstructured":"Minnella\u00a0AM, Rissotto\u00a0R, Antoniazzi\u00a0E et\u00a0al (2021) Ocular involvement in hereditary amyloidosis. Genes (Basel) 12:955","journal-title":"Genes (Basel)"},{"key":"1569_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed\u00a0SF, Mirzoyev\u00a0SA, Edwards\u00a0WD et\u00a0al (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113\u2013122","journal-title":"JACC Heart Fail"},{"key":"1569_CR19","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1073\/pnas.0400062101","volume":"101","author":"N Reixach","year":"2004","unstructured":"Reixach\u00a0N, Deechongkit\u00a0S, Jiang\u00a0X et\u00a0al (2004) Tissue damage in the amyloidosis: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S\u00a0A 101:2817\u20132822","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1569_CR20","doi-asserted-by":"publisher","first-page":"E2403","DOI":"10.1002\/humu.22619","volume":"35","author":"DM Rowczenio","year":"2014","unstructured":"Rowczenio\u00a0DM, Noor\u00a0I, Gillmore\u00a0JD et\u00a0al (2014) Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 35:E2403\u2013E2412","journal-title":"Hum Mutat"},{"key":"1569_CR21","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.bpj.2016.09.010","volume":"111","author":"L Sartiani","year":"2016","unstructured":"Sartiani\u00a0L, Bucciantini\u00a0M, Spinelli\u00a0V et\u00a0al (2016) Biochemical and electrophysiological modification of amyloid transthyretin on cardiomyocytes. Biophys\u00a0J 111:2024\u20132038","journal-title":"Biophys J"},{"key":"1569_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, Adams\u00a0D, Kristen\u00a0A et al (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study. Circulation 139:431\u2013443","journal-title":"Circulation"},{"key":"1569_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen\u00a0M, Peuralinna\u00a0T, Polvikovski\u00a0T et al (2008) Senile systemic amyloidosis affects 25\u202f% of the very aged and associates with genetic variation in apha2-macroglobulin and tau: a\u00a0population-based autopsy study. Ann Med 40:232\u2013239","journal-title":"Ann Med"},{"key":"1569_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCIMAGING.116.005066","volume":"9","author":"TA Treibel","year":"2016","unstructured":"Treibel\u00a0TA, Fontana\u00a0M, Gilbertson\u00a0JA et\u00a0al (2016) Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 9:1\u20139","journal-title":"Circ Cardiovasc Imaging"},{"key":"1569_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12181-019-00344-5","volume":"13","author":"A Yilmaz","year":"2019","unstructured":"Yilmaz\u00a0A, Bauersachs\u00a0J, Kindermann\u00a0I et al (2019) Diagnostik und Therapie der kardialen Amyloidose. Positionspapier der Deutschen Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung (DGK). Kardiologe 13:264\u2013291","journal-title":"Kardiologe"},{"key":"1569_CR26","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1021\/bi301313b","volume":"52","author":"L Zhao","year":"2013","unstructured":"Zhao\u00a0L, Buxbaum\u00a0JN, Reixach\u00a0N (2013) Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 52:1913\u20131926","journal-title":"Biochemistry"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01569-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01569-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01569-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:02:56Z","timestamp":1692806576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01569-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1569"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01569-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"17 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Czepluch gibt Honorare f\u00fcr Beratungs- und Referentent\u00e4tigkeit von Pfizer Pharma und Alnylam Therapeutics und Reisekostenunterst\u00fctzung von Alnylam Therapeutics an.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}